International Application No. rCT/EP02/00991
International Filing Date: 31 January 2002

Amendments to the Claims:

1. (Original) A compound of formula (I),



(I)

wherein,

R^1 is selected from H, halo, -CN, $-CF_3$, C_{1-4} alkyl or C_{1-4} alkoxy;

R^2 is selected from $-(CH_2)_n$-phenyl, $-(CH_2)_n$-heterocyclyl, $-(CH_2)_n$-heteroaryl, each of which may be further substituted by one or more substituents, which may be the same or different, selected from halo (such as fluoro, chloro, bromo), -CN, $-CF_3$, -OH, $-OCF_3$, C_{1-4} alkyl or C_{1-4} alkoxy, $-NO_2$, $-NH_2$, $-NR^3R^4$, $-CONR^3R^4$, $-NHCOR^3$, $-SO_2R^3$, $-SO_2NHR^3$, $-O(CH_2)_mNR^3R^4$;

R^3 is selected from H or C_{1-4} alkyl;

R^4 is selected from heterocyclyl or heteroaryl

n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2 or 3;

X and X', which may be the same or different, are each selected from CH or N, provided that X and X' are not both N,

and salts and solvates thereof.

2. (Original) A compound of formula (I) as claimed in claim 1, wherein R^1 is positioned at the C(3) or C(6) position of the pyridine ring and is selected from H, halo, -CN, $-CF_3$, C_{1-4} alkyl or C_{1-4} alkoxy.

3. (Original) A compound of formula (I) as claimed in claim 2, wherein R^1 is H.

4. (Currently Amended) A compound of formula (I) as claimed in ~~any one of claims 1 to 3~~ claim 1, wherein R^2 is $-(CH_2)_n$-phenyl, which may be further substituted by one or more substituents, which may be the same or different, selected from halo (such as fluoro, chloro, bromo), -CN, $-CF_3$, -OH, $-OCF_3$, C_{1-4} alkyl or C_{1-4} alkoxy, $-NO_2$, $-NH_2$, $-NR^3R^4$, $-CONR^3R^4$, $-NHCOR^3$, $-SO_2R^3$, $-SO_2NHR^3$, $-O(CH_2)_mNR^3R^4$.

5. (Currently Amended) A compound of formula (I) as claimed ~~in any one of claims 1 to 4~~ claim 1 wherein n is 0 or1.

6. (Original) A compound of formula (I) as claimed in claim 1 selected from:

[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-yl]-phenyl-amine;

[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine;

[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-yl]-(4-fluoro-phenyl)-amine;

5-[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-ylamino]-2-methoxy-phenol;

3-[4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-ylamino]-N-methyl-benzamide; and N-{4-(2-Amino-4-pyridin-2-yl-thiazol-5-yl)-pyridin-2-ylamino]-phenyl}-acetamide;

and salts and solvates thereof.

7. (Currently Amended) A pharmaceutical composition comprising at least one compound of formula (I) as claimed in ~~any one of claims 1 to 6~~ claim 1, together with a pharmaceutically acceptable diluent or carrier.

8. (Currently Amended) A compound of formula (I) as claimed in ~~any one of claims 1 to 6~~ claim 1, for use as a medicament.

9. Cancelled.

10. (CurrentlyAmended) A method for the treatment of a human or animal subject with a disorder characterised by the overexpression of TGF-β, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as claimed in ~~any one of claims 1 to 6~~ claim 1 or a physiologically acceptable salt or solvate thereof.

11. (Original) A process for the preparation of a compound of formula (I),



(I)

wherein,

R^1 is selected from H, halo, -CN, $-CF_3$, C_{1-4} alkyl or C_{1-4} alkoxy;

R^2 is selected from $-(CH_2)_n$-phenyl, $-(CH_2)_n$-heterocyclyl, $-(CH_2)_n$-heteroaryl, of which may be further substituted by one or more substituents, which may be the same or different, selected from halo (such as fluoro, chloro, bromo), -CN, $-CF_3$, -OH, $-OCF_3$, C_{1-4} alkyl or C_{1-4} alkoxy, $-NO_2$, $-NH_2$, $-NR^3R^4$, $-CONR^3R^4$, $-NHCOR^3$, $-SO_2R^3$, $-SO_2NHR^3$, $-O(CH_2)_mNR^3R^4$;

R^3 is selected from H or C_{1-4} alkyl;

R^4 is selected from heterocyclyl or heteroaryl

n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2 or 3;

X and X', which may be the same or different, are each selected from CH or N, provided that X and X' are not both N,

and salts and solvates thereof,

International Application No. PCT/EP02/00991
International Filing Date: 31 January 2002

which process comprises:

a) treatment of a compound of formula (X) with an amine R^2NH_2 in the presence of $Pd_2(dba)_2$ and binap,



(X)

b) subsequent removal of the protecting group from the resulting product.